For the Inventor, By the Inventor

Enter assignee name

Irvine, CA, United States of America

Allergan, Inc.

USPTO Granted Patents = 2,287

% Expired Patents = 24.4

CIPO Patents = 126

EPO Patents = 511

Trademarks = 158

Forward Citations = 50,629

Loading Chart...

Loading Chart...

885 inventors (with patents filed for the assignee):

Michael E Garst (189 out of 212 patents)

Roshantha A Chandraratna (156 out of 291 patents)

John E Donello (135 out of 136 patents)

4. Robert M Burk (134 out of 166 patents)

5. Ken Chow (120 out of 124 patents)

6. Kei Roger Aoki (117 out of 126 patents)

7. Richard L Beard (117 out of 138 patents)

8. David W Old (111 out of 115 patents)

9. Lance Steward (101 out of 102 patents)

10. David Frederick Woodward (98 out of 113 patents)

11. Patrick Michael Hughes (83 out of 90 patents)

12. Daniel W Gil (75 out of 84 patents)

13. Ester Fernandez-Salas (72 out of 76 patents)

14. Larry Allen Wheeler (68 out of 76 patents)

15. James Nienyuan Chang (64 out of 68 patents)

Core Competencies:

Hyaluronic Acid

Botulinum Toxin

Tissue Augmentation

Injection Devices

Dermal Filling

Soft Tissue

Pharmaceutical Compositions

Microneedles

Ocular Conditions

Anti-Microbial Efficacy

Prostaglandin Receptors

Biodegradable Implants

2,287 patents: Sort by Forward Citations

1. 12599699 - Co-crosslinked hyaluronic acid-silk fibroin hydrogels for improving tissue graft viability and for soft tissue augmentation (2026-04-14),

2. 12527816 - Sodium chlorite compositions with enhanced anti-microbial efficacy and reduced toxicity (2026-01-20),

3. 12409211 - Non-protein Clostridial toxin compositions (2025-09-09),

4. 12241098 - Process and system for obtaining botulinum neurotoxin (2025-03-04),

5. 12208155 - Method for improving duration of effect of dermal filler treatment (2025-01-28),

6. 12171816 - Non-protein Clostridial toxin compositions (2024-12-24),

7. 12144847 - Non-protein clostridial toxin compositions (2024-11-19),

8. 12004995 - Intraocular implant with high loading of a prostamide (2024-06-11),

9. 11992668 - Injection device (2024-05-28),

10. D1027647 - Bottle holder (2024-05-21),

11. 11944533 - Implantable prostheses for tissue expansion (2024-04-02),

12. 11890457 - Aspiration and injection device (2024-02-06),

13. 11844878 - Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation (2023-12-19),

14. 11833269 - Hyaluronic acid-collagen matrices for dermal filling and volumizing applications (2023-12-05),

15. 11819541 - Injection paradigm for administration of botulinum toxins (2023-11-21),

Company Overview

Allergan, Inc., headquartered in Irvine, California, is a leading company in the field of dermal fillers, specializing in innovative aesthetic and therapeutic solutions. The organization focuses on the development and manufacturing of products that utilize core technologies such as hyaluronic acid and botulinum toxin for tissue augmentation and soft tissue enhancement. Allergan's expertise extends to advanced injection devices and pharmaceutical compositions, positioning it as a key player in the cosmetic and medical dermatology sectors.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

2,287 Patents

#3 in Irvine, CA

#55 in California

#221 in US

#445 in the World

Irvine, CA, United States of America

Allergan, Inc.

Forward Citations = 50,629

885 inventors:

Michael E Garst (189 out of 212 patents)

Roshantha A Chandraratna (156 out of 291 patents)

John E Donello (135 out of 136 patents)

4. Robert M Burk (134 out of 166 patents)

5. Ken Chow (120 out of 124 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Allergan, Inc.. Retrieved from https://idiyas.com/company/allergan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…